Retrospective Analysis of the Clinical… | Clinical Trial

Key information

Conditions

Retinal Vein Occlusion Cardiovascular Diseases Embolism and Thrombosis Eye Diseases Retinal Diseases Thrombosis Vascular Diseases Venous Thrombosis

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430071, China

About this study

To explore the clinical characteristics of patients with RVO, and to analyze the relationship between RVO and various underlying diseases, ocular conditions, lifestyle, imaging findings and treatment response. To systematically analyze the clinical data of patients with different types of RVO, further reveal the potential mechanism of its occurrence and development, and evaluate the efficacy and safety of different treatment methods, in order to provide more scientific basis for clinical treatment.

Patients discharged from our hospital from January 2018 to December 2024 with the diagnosis of retinal vein occlusion were retrospectively investigated. The medical history of each patient was reviewed, and the basic information, past medical history, eye examinations and their results, treatment plans, and prognosis information of the patients were recorded in detail.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

meeting the diagnostic criteria for RVO (including BRVO and CRVO)

Exclusion criteria

patients with other ocular diseases other than RVO, such as iridocyclitis, age-related macular degeneration, central serous chorioretinopathy and optic neuropathy;
patients with systemic inflammatory diseases and other systemic diseases other than diabetes, hypertension, coronary heart disease and cerebral infarction that may affect blood indexes;
patients with incomplete clinical data and information.

Treatment and study plan

Primary outcomes

Various underlying diseases, eye conditions, lifestyle, blood test results, imaging manifestations and treatment response

Time frame: From January 2024 to January 2025

Age, gender, blood routine (platelet count, neutrophil count, monocyte count, and lymphocyte count), four coagulation tests (prothrombin time determination, activated partial thromboplastin time determination), blood lipid (total cholesterol, triglyceride, high density lipoprotein, low density lipoprotein data), hypertension, diabetes, coronary heart disease, and cerebral infarction were collected in detail Death history, laser, anti-VEGF injection, hormone and other treatment methods and times, and the visual acuity at the last follow-up. The general conditions of the patients were statistically analyzed, such as the proportion of previous history of hypertension and diabetes, and the mean value of blood lipids, blood clotting images and other blood test results of the patients were calculated, and the correlation between them and the prognosis of vision was analyzed.

Sponsors and collaborators

Lead sponsor

Zhongnan Hospital

Other

Registry information

Important dates

Study start: 2018
Primary completion: 2024
Study completion: 2024
First posted: Jan 3, 2025
Registry last updated: Jan 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed